Vaxart Inc Stock Analysis

Vaxart Stock Analysis Notes

About 18.0% of the company outstanding shares are owned by institutional investors. The book value of Vaxart was at this time reported as 0.38. The company recorded a loss per share of 0.4. Vaxart Inc last dividend was issued on the 9th of November 2012. The entity had 1:11 split on the 14th of February 2018. Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. For more information please call Cezar MBA at 650 550 3500 or visit https://vaxart.com.

Vaxart Inc Investment Alerts

Vaxart Inc Upcoming and Recent Events

Vaxart Largest EPS Surprises

View All Earnings Estimates

Vaxart Stock Institutional Investors

Note, although Vaxart's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vaxart Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 138.26 M.

Vaxart Profitablity

Management Efficiency

Vaxart Inc has return on total asset (ROA) of (0.3968) % which means that it has lost $0.3968 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9166) %, meaning that it created substantial loss on money invested by shareholders. Vaxart's management efficiency ratios could be used to measure how well Vaxart manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.94 in 2024. Return On Capital Employed is likely to gain to -1.01 in 2024. At this time, Vaxart's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 150.6 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 2.8 M in 2024.

Technical Drivers

As of the 22nd of November, Vaxart has the Variance of 14.21, risk adjusted performance of (0.09), and Coefficient Of Variation of (810.05). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vaxart Inc, as well as the relationship between them.

Vaxart Inc Price Movement Analysis

Vaxart Inc Insider Trading Activities

Vaxart Outstanding Bonds

Vaxart Predictive Daily Indicators

Vaxart Forecast Models

Vaxart's time-series forecasting models are one of many Vaxart's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vaxart's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vaxart prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vaxart shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vaxart. By using and applying Vaxart Stock analysis, traders can create a robust methodology for identifying Vaxart entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vaxart analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vaxart analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Vaxart Inc stock analysis indicators help investors evaluate how Vaxart stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vaxart shares will generate the highest return on investment. By understating and applying Vaxart stock analysis, traders can identify Vaxart position entry and exit signals to maximize returns.

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.